Citadel Advisors’s Pacific Biosciences PACB Stock Holding History

Citadel Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.1K	Sell	53,900 -95,300	-64%	-$170K	﹤0.01%	12240
2025 Q4	$279K	Sell	149,200 -45,800	-23%	-$88K	﹤0.01%	10303
2025 Q3	$250K	Sell	195,000 -139,900	-42%	-$189K	﹤0.01%	10763
2025 Q2	$415K	Buy	334,900 +145,700	+77%	+$168K	﹤0.01%	9063
2025 Q1	$223K	Sell	189,200 -106,000	-36%	-$163K	﹤0.01%	10234
2024 Q4	$540K	Buy	295,200 +64,700	+28%	+$126K	﹤0.01%	8381
2024 Q3	$392K	Sell	230,500 -900	-0.4%	-$1.48K	﹤0.01%	8764
2024 Q2	$317K	Sell	231,400 -29,800	-11%	-$60.2K	﹤0.01%	9029
2024 Q1	$980K	Buy	261,200 +1,300	+0.5%	+$7.61K	﹤0.01%	6954
2023 Q4	$2.55M	Sell	259,900 -14,800	-5%	-$121K	﹤0.01%	4944
2023 Q3	$2.29M	Sell	274,700 -74,300	-21%	-$849K	﹤0.01%	4967
2023 Q2	$4.64M	Buy	349,000 +95,100	+37%	+$1.16M	﹤0.01%	3754
2023 Q1	$2.94M	Sell	253,900 -44,100	-15%	-$438K	﹤0.01%	4665
2022 Q4	$2.44M	Buy	298,000 +257,800	+641%	+$2.22M	﹤0.01%	5115
2022 Q3	$233K	Sell	40,200 -1,300	-3%	-$7.46K	﹤0.01%	10097
2022 Q2	$183K	Sell	41,500 -500	-1%	-$3.04K	﹤0.01%	10801
2022 Q1	$382K	Buy	42,000 +2,000	+5%	+$23K	﹤0.01%	10027
2021 Q4	$818K	Sell	40,000 -184,900	-82%	-$4.46M	﹤0.01%	8437
2021 Q3	$5.75M	Buy	224,900 +103,900	+86%	+$3.08M	﹤0.01%	4042
2021 Q2	$4.23M	Sell	121,000 -52,600	-30%	-$1.53M	﹤0.01%	4805
2021 Q1	$5.78M	Buy	173,600 +10,900	+7%	+$382K	﹤0.01%	3954
2020 Q4	$4.22M	Buy	162,700 +120,900	+289%	+$2.05M	﹤0.01%	3962
2020 Q3	$413K	Buy	41,800 +17,700	+73%	+$102K	﹤0.01%	7609
2020 Q2	$83K	Buy	24,100 +4,200	+21%	+$14.3K	﹤0.01%	9091
2020 Q1	$61K	Buy	+19,900	New	+$81.5K	﹤0.01%	8933
2019 Q3	–	Sell	-19,000	Closed	-$115K	–	9601
2019 Q2	$115K	Buy	+19,000	New	+$133K	﹤0.01%	8485
2019 Q1	–	Sell	-23,100	Closed	-$171K	–	9708
2018 Q4	$171K	Sell	23,100 -21,600	-48%	-$137K	﹤0.01%	7974
2018 Q3	$242K	Buy	+44,700	New	+$192K	﹤0.01%	7932
2018 Q1	–	Sell	-26,400	Closed	-$70K	–	8640
2017 Q4	$70K	Buy	26,400 +2,800	+12%	+$9.8K	﹤0.01%	7537
2017 Q3	$124K	Buy	+23,600	New	+$101K	﹤0.01%	6956
2017 Q2	–	Sell	-26,800	Closed	-$139K	–	7895
2017 Q1	$139K	Sell	26,800 -3,900	-13%	-$19.1K	﹤0.01%	6723
2016 Q4	$117K	Sell	30,700 -17,400	-36%	-$126K	﹤0.01%	6610
2016 Q3	$431K	Buy	48,100 +22,700	+89%	+$190K	﹤0.01%	5083
2016 Q2	$179K	Sell	25,400 -11,500	-31%	-$105K	﹤0.01%	5909
2016 Q1	$314K	Buy	36,900 +3,200	+9%	+$31.5K	﹤0.01%	5040
2015 Q4	$442K	Buy	33,700 +28,500	+548%	+$256K	﹤0.01%	4627
2015 Q3	$19K	Sell	5,200 -1,700	-25%	-$8.31K	﹤0.01%	8195
2015 Q2	$40K	Buy	+6,900	New	+$39.9K	﹤0.01%	7810
2015 Q1	–	Sell	-4,600	Closed	-$36K	–	8759
2014 Q4	$36K	Sell	4,600 -7,600	-62%	-$48.6K	﹤0.01%	7432
2014 Q3	$60K	Buy	12,200 +3,200	+36%	+$16.7K	﹤0.01%	6788
2014 Q2	$56K	Buy	+9,000	New	+$45K	﹤0.01%	6678

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's PACB Position: Q1 2026 in Review

Citadel Advisors reduced its Pacific Biosciences (PACB) stake by 50% in Q1 2026, selling an estimated $2.84M and leaving 1,576,051 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5984.

Citadel Advisors first reported a position in PACB in Q4 2013 and has held it in 46 quarters since. The position peaked at $58.5M in Q1 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Citadel Advisors held 1,576,051 shares of Pacific Biosciences worth $2.08M as of Q1 2026.
Citadel Advisors sold 1,590,190 Pacific Biosciences shares in Q1 2026, an estimated $2.84M.
Pacific Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5984 holding.
Citadel Advisors first reported a position in Pacific Biosciences in Q4 2013 and has held it in 46 quarters since.
Citadel Advisors's Pacific Biosciences position peaked at $58.5M in Q1 2023.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.